argenx SE
XBRU:ARGX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
298.7
577.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
argenx SE
argenx SE
Revenue
argenx SE
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
argenx SE
XBRU:ARGX
|
Revenue
$1.9B
|
CAGR 3-Years
44%
|
CAGR 5-Years
87%
|
CAGR 10-Years
126%
|
|
|
Pharming Group NV
AEX:PHARM
|
Revenue
$285.7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
51%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Revenue
€21.3m
|
CAGR 3-Years
113%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Revenue
$28.6m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
36%
|
CAGR 10-Years
18%
|
|
|
Merus NV
NASDAQ:MRUS
|
Revenue
$35.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Revenue
$6.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
argenx SE
Revenue Breakdown
Breakdown by Geography
argenx SE
|
Total Revenue:
1.2B
USD
|
|
United States:
1B
USD
|
|
EMEA:
72.9m
USD
|
|
Japan:
56.4m
USD
|
|
China:
14.9m
USD
|
Breakdown by Segments
argenx SE
argenx SE
Glance View
Argenx SE is an innovative biopharmaceutical company that focuses on developing antibody therapies to address severe autoimmune diseases and cancers. Founded in 2008 and headquartered in the Netherlands, Argenx utilizes its proprietary antibody engineering platform, known as the "Differentiated Antibody Platform," to discover and advance therapies with the potential to provide significant benefits over existing treatments. Their lead product, efgartigimod, has garnered attention for its ability to modulate the immune system and effectively reduce the debilitating symptoms of autoimmune conditions like myasthenia gravis. With a growing pipeline that promises to expand the company's reach into additional therapeutic areas, Argenx is positioned as a key player in the healthcare sector, making it an attractive opportunity for investors looking for growth within a dynamic industry. Argenx's commitment to innovation is further underscored by its strong international presence, with collaborations and partnerships that enhance its research capabilities and market access. The company's financial health is bolstered by strategic funding initiatives, including significant collaborations with larger pharmaceutical firms, which provide not only capital but also expertise and resources to accelerate development. As Argenx continues to advance its clinical programs and receive regulatory approvals, its ability to deliver transformative therapies presents a compelling narrative of growth and potential profitability. For investors, Argenx stands out as a forward-thinking enterprise that embodies the principles of disciplined investment through sustainable innovation and long-term value creation.
See Also
What is argenx SE's Revenue?
Revenue
1.9B
USD
Based on the financial report for Jun 30, 2024, argenx SE's Revenue amounts to 1.9B USD.
What is argenx SE's Revenue growth rate?
Revenue CAGR 10Y
126%
Over the last year, the Revenue growth was 68%. The average annual Revenue growth rates for argenx SE have been 44% over the past three years , 87% over the past five years , and 126% over the past ten years .
You don't have any saved screeners yet
